The weights of the mice were recorded weekly from the day a tumour was first detected. The mean weight at the start of treatment was 29.5 ± 0.7 (s.em.) g, range 24-34 g. Weekly prophylactic tail-vein injections of 6 mg kg-' DOX-SL were started when the progr growth of a tumour was verified, at an average size of 0.2 cm3. Tumours were excised when they rhed a volume of 0.8-1.0 cm3, at which time the treatments were stopped. Following tumour excision, a mouse was seected for euthanasia by carbon dioxide asphyxiation when it appeared to be in poor health, or no later than 6 weeks after surgery. All mice were necropsied, and the visceral organs removed. The lungs were examined for metastases by taing four stepwise, 5 pm sections of each of the five lobes. The quantity of metastases per mouse was graded on a scale of 0-5 shown in Table I .
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The therapeutic efficacy of doxorubicin was found to be increased and its toxic sidefects reduced (Vaa et al., 1993) (Vaage et al., 1986) . About half of the tumours will produce pulmonary metastases in the original host (Vaage and Harlos, 1987 Table I .
Resdks
The results presented in Table H show that weekly injections of 6mg kg-' DOX-SL effectively inhibited the development of metastases from mammary carcinomas (X = 7.9, P< 0.005) and prolonged mean survival from 59 days in the placebo group to 88.7 days in the treated group (t = 3.53, P<0.001). The tumours in untreated mice grew progressively, and were surgically removed, 17 ± 0.6 days after detection, at an average size of 0.9 ± 0.08 cm3. In the treated mice (Vaage et al., 1992) .
